An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 12/7/2018 |
| Start Date: | June 15, 2019 |
| End Date: | July 11, 2023 |
| Contact: | Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, |
| Email: | Clinical.Trials@bms.com |
| Phone: | please email |
A Randomized, Active-Controlled, Open-Label, Phase 2 Clinical Trial of BMS-986213, in Combination With Various Standard-of-Care Therapeutic Regimens, in Participants With Recurrent, Locally Advanced, or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction (GEJ) Adenocarcinoma
The purpose of this study is to determine the effectiveness of relatlimab plus nivolumab,
alone or in combination with various standard-of-care treatments in participants with gastric
cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to
other places in the body after prior therapy.
alone or in combination with various standard-of-care treatments in participants with gastric
cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma that has come back or spread to
other places in the body after prior therapy.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- Histologically or cytologically confirmed locally advanced or recurrent or metastatic
GC or GEJ adenocarcinoma that is considered incurable by local therapies such as
radiation or surgery
- Evidence of progressive disease (PD) on at least one prior platinum- and
fluoropyrimidine-containing chemotherapy regimen
- Available tumor tissue for biomarker analysis
Exclusion Criteria:
- Must not have squamous cell or undifferentiated GC or GEJ
- Untreated known central nervous system (CNS) metastases
- Uncontrolled or significant cardiovascular disease
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
21
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials